RSS-Feed abonnieren
DOI: 10.1055/s-0032-1325618
Aspirin-Exacerbated Respiratory Disease: Update on Pathogenesis and Desensitization
Publikationsverlauf
Publikationsdatum:
09. Oktober 2012 (online)
![](https://www.thieme-connect.de/media/srccm/201206/lookinside/thumbnails/10.1055-s-0032-1325618-1.jpg)
Abstract
Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma. These patients tend to have progressive and recalcitrant sinus disease requiring frequent surgical intervention and in many cases systemic corticosteroids. Much about the pathogenesis of AERD remains unclear, but environmental factors likely play a prominent role in its development. Avoidance of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) is imperative in the initial counseling of these patients. Because most of the exposure to these medications is available over the counter, most patients will experience a significant respiratory reaction to full therapeutic doses of seemingly innocent NSAIDs. Although the history of a reaction to aspirin or another NSAID is a very important part of making the diagnosis, the gold standard remains an observed aspirin challenge. Given the prevalence and usefulness of aspirin and NSAID therapy in primary care clinics, an accurate diagnosis should be made in all patients. Desensitization is an effective treatment option for many patients. Recent advances have made this procedure considerably safer and outpatient aspirin desensitization is now the standard of care.
-
References
- 1 Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28 (4) 717-722
- 2 Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57 (7) 569-574
- 3 Kasper L, Sladek K, Duplaga M , et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58 (10) 1064-1066
- 4 Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004; 34 (10) 1597-1601
- 5 Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328 (7437) 434-437
- 6 Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007; 86 (7) 396-399
- 7 Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008; 100 (5) 420-425
- 8 Szczeklik A, Nizankowska E, Duplaga M ; AIANE Investigators. European Network on Aspirin-Induced Asthma. Natural history of aspirin-induced asthma. Eur Respir J 2000; 16 (3) 432-436
- 9 Lumry WR, Curd JG, Zeiger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol 1983; 71 (6) 580-587
- 10 Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983; 71 (6) 574-579
- 11 White AA, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of OACs. Ann Allergy Asthma Immunol 2006; 97 (5) 688-693
- 12 Chen AH, Bennett CR. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesth Prog 1994; 41 (4) 102-107
- 13 Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103 (6) 890-892
- 14 Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96 (4) 480-485
- 15 Gyllfors P, Bochenek G, Overholt J , et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003; 111 (5) 1116-1121
- 16 Woessner K, Simon RA, Stevenson DD. The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum 2002; 46 (8) 2201-2206
- 17 Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108 (1) 47-51
- 18 Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 2007; 142 (1) 64-69
- 19 Chang JE, Ding D, White AA, Martin J, Stevenson DD. Smoking, environmental tobacco smoke, and aspirin exacerbated respiratory disease [abstract]. J Allergy Clin Immunol 2011; 127: AB135
- 20 Jafek BW, Smith CM, Moran DT, Johnson EW, Eller PM. Effects on the upper respiratory passages. Otolaryngol Head Neck Surg 1992; 106 (6) 720-729
- 21 Bascom R, Kesavanathan J, Fitzgerald TK, Cheng KH, Swift DL. Sidestream tobacco smoke exposure acutely alters human nasal mucociliary clearance. Environ Health Perspect 1995; 103 (11) 1026-1030
- 22 Tamashiro E, Xiong G, Anselmo-Lima WT, Kreindler JL, Palmer JN, Cohen NA. Cigarette smoke exposure impairs respiratory epithelial ciliogenesis. Am J Rhinol Allergy 2009; 23 (2) 117-122
- 23 Rusznak C, Sapsford RJ, Devalia JL , et al. Cigarette smoke potentiates house dust mite allergen-induced increase in the permeability of human bronchial epithelial cells in vitro. Am J Respir Cell Mol Biol 1999; 20 (6) 1238-1250
- 24 Ronchetti R, Macri F, Ciofetta G , et al. Increased serum IgE and increased prevalence of eosinophilia in 9-year-old children of smoking parents. J Allergy Clin Immunol 1990; 86 (3 Pt 1) 400-407
- 25 Taylor RG, Gross E, Joyce H, Holland F, Pride NB. Smoking, allergy, and the differential white blood cell count. Thorax 1985; 40 (1) 17-22
- 26 Eddleston J, Lee RU, Doerner AM, Herschbach J, Zuraw BL. Cigarette smoke decreases innate responses of epithelial cells to rhinovirus infection. Am J Respir Cell Mol Biol 2011; 44 (1) 118-126
- 27 Davoine F, Cao M, Wu Y , et al. Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells. J Allergy Clin Immunol 2008; 122 (1) 69-77 , 77, e1–e2
- 28 Huang YJ, Nelson CE, Brodie EL , et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127 (2) 372-381 , e1–e3
- 29 Samter M, Beers Jr RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68 (5) 975-983
- 30 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111 (5) 913-921 , quiz 922
- 31 Sestini P, Armetti L, Gambaro G , et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153 (2) 572-575
- 32 Christie PE, Tagari P, Ford-Hutchinson AW , et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143 (5 Pt 1) 1025-1029
- 33 Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999; 104 (3 Pt 1) 559-564
- 34 Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118 (4) 773-786 , quiz 787–788
- 35 Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347 (19) 1493-1499
- 36 Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111 (1) 180-186
- 37 Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90 (3) 338-341
- 38 Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007; 119 (1) 157-164
- 39 Rozsasi APD, Polzehl D, Deutschle T , et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008; 63 (9) 1228-1234
- 40 Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69 (1 Pt 1) 11-19
- 41 Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006; 118 (4) 801-804
- 42 Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 2010; 126 (4) 738-744
- 43 Borish L, Rosenwasser LJ. Cytokines in allergic inflammation. In: Adkinson NJ, Busse WW, Bochner BS, Holgate ST, Lemanske RF, Simons FER, , eds. Middleton: Allergy Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2009: 165-179
- 44 Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 2009; 124 (4) 724-730 , e4
- 45 Cianferoni A, Schroeder JT, Kim J , et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97 (6) 1742-1749
- 46 Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 2002; 168 (3) 1428-1434
- 47 Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96 (2) 148-156
- 48 Arm JP, O'Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989; 140 (1) 148-153
- 49 Sanak M, Szczeklik A. Leukotriene C4 synthase polymorphism and aspirin-induced asthma. J Allergy Clin Immunol 2001; 107: 561-562
- 50 Dahlén SE, Malmström K, Nizankowska E , et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (1) 9-14
- 51 White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 95 (4) 330-335
- 52 White AA, Bigby TA, Stevenson DD. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006; 97 (2) 190-195
- 53 Lee RU, White AA, Ding D , et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105 (2) 130-135